News Release
Mallinckrodt to Present at Morgan Stanley 2014 Global Healthcare Conference
DUBLIN--(BUSINESS WIRE)--Aug. 25, 2014--
Mallinckrodt
plc (NYSE: MNK), a leading global specialty pharmaceutical company, will
present at the Morgan Stanley Global Healthcare Conference in New York
on Monday, September 8, 2014. Mark Trudeau, President and Chief
Executive Officer of Mallinckrodt, will represent the company in a
session scheduled to begin at 9:20 AM, Eastern Time.
Individuals who are unable to attend the meeting can access a replay
through the following link: http://www.mallinckrodt.com/investor_relations
ABOUT MALLINCKRODT:
Mallinckrodt is a global specialty pharmaceutical and medical imaging
business that develops, manufactures, markets and distributes specialty
pharmaceutical products and medical imaging agents. Areas of focus
include analgesics and CNS drugs for prescribing by office- and
hospital-based physicians, and autoimmune and rare disease specialty
areas like neurology, rheumatology, nephrology and pulmonology. The
company's core strengths include the acquisition and management of
highly regulated raw materials; deep regulatory expertise; and
specialized chemistry, formulation and manufacturing capabilities. The
company's Specialty Pharmaceuticals segment includes branded and
specialty generic drugs and active pharmaceutical ingredients, and the
Global Medical Imaging segment includes contrast media and nuclear
imaging agents. Mallinckrodt has more than 5,500 employees worldwide and
a commercial presence in roughly 65 countries. The company's fiscal 2013
revenue totaled $2.2 billion. To learn more about Mallinckrodt, visit www.mallinckrodt.com.
Source: Mallinckrodt
Mallinckrodt
John Moten, 314-654-6650
Vice President, Investor
Relations
john.moten@mallinckrodt.com
or
Lynn
Phillips, 314-654-3263
Manager, Communications
lynn.phillips@mallinckrodt.com
